ArticleDrugs in R&D2026
Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.
Article in Drugs in R&D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesClaudin18.2 (CLDN18.2) is a promising therapeutic target overexpressed in various tumor tissues. While CD3-engaging bispecific antibodies show great potential, their clinical application is often limited by poor efficacy in solid tumors and significant safety risks, such as cytokine release syndrome (CRS). The objective of this study was to comprehensively evaluate the preclinical anti-tumor efficacy, pharmacokinetics, tissue distribution, and safety profile of AHT-102, a novel Fc-free CLDN18.2 × CD3 bispecific antibody with a low-affinity CD3 arm, to determine its potential for clinical development.
methodsThis study evaluated the anti-tumor efficacy of AHT-102 in CLDN18.2-positive gastric cancer mouse models (NUGC4-CLDN18.2). We further assessed its pharmacokinetic characteristics, quantitative tissue distribution using
resultsAHT-102 (0.1, 0.3, and 1 mg/kg) demonstrated significant dose-dependent anti-tumor effects, with tumor weight inhibition reaching 51% at the 1-mg/kg dose. Pharmacokinetic analysis in CD3EDG mice revealed linear characteristics with refined terminal half-lives of 0.762 h, 3.05 h, and 4.25 h for doses of 0.1, 0.5, and 2.5 mg/kg, respectively. Tissue distribution studies confirmed superior targeting specificity; the tumor-to-muscle ratio exceeded 15, and the molecule successfully bypassed the 'T-cell sink' by showing lower accumulation in the lymph nodes compared with the tumor. In vitro, AHT-102 did not induce target-independent cytokine release from peripheral blood mononuclear cells (PBMCs). The maximum tolerated dose (MTD) in human CD3EDG mice reached 13.65 mg/kg, a 136.5-fold margin over the projected clinical starting dose. Observed gastric tissue damage was dose-dependent and reversible upon drug discontinuation.
conclusionsAHT-102, a novel Fab-like bispecific antibody, achieves an optimized therapeutic balance through its low-affinity CD3 arm and Fc-free format. It demonstrates significant anti-tumor efficacy and exceptional targeting specificity while avoiding systemic immunotoxicity typically associated with CD3-targeting agents. These findings provide a robust scientific rationale for the clinical translation of AHT-102 in patients with CLDN18.2-positive cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.